Strategic merger and post-merger plans to propel 메이저 바카라 Group toward global pharmaceutical leadership.
메이저 바카라 Group, led by Chairman Jung-Jin Seo, disclosed on the morning of October 23rd that the merger resolutions of both 메이저 바카라 and 메이저 바카라 Healthcare have been overwhelmingly approved at their respective temporary shareholders' meetings held at Incheon Songdo Convensia and Sheraton Grand Incheon Hotel.
In August of this year, both companies had resolved to merge, and in today's shareholder meetings, a substantial majority of shareholders expressed their support for the merger proposal. 메이저 바카라 received an impressive 97.04% approval, while 메이저 바카라 Healthcare secured a commendable 95.17% approval. The merger is slated for completion by year-end, with the merger date scheduled for December 28th, followed by a period for exercising stock purchase rights until January 13th of the following year.
The merger between 메이저 바카라 and 메이저 바카라 Healthcare follows the 'absorption merger' structure, where 메이저 바카라 issues its new shares to the shareholders of 메이저 바카라 Healthcare. Each 메이저 바카라 Healthcare common share will be exchanged for 0.4492620 shares of 메이저 바카라 common stock. The per-share merger price is set at 9.99 for 메이저 바카라 and .41 for 메이저 바카라 Healthcare.
Conversely, 메이저 바카라 Group held a board meeting on this day and decided to enhance shareholder value and return policies post-merger. They have granted approval for the repurchase of their own shares and additional purchases. The shares to be repurchased amount to 2,309,813 shares of 메이저 바카라, with an approximate value of 5.8 million. These shares align with the size equivalent to the new shares allocated to 메이저 바카라 Healthcare's own shares held post-merger. The repurchase date is scheduled for January 4, 2024, following the completion of merger registration.
On the same day, it was decided that 메이저 바카라 would acquire a total of 2,426,161 shares, with an estimated amount of around 4.7 million. Additionally, 메이저 바카라 Healthcare is poised to acquire a total of 2,440,000 shares, amounting to approximately 4.5 million. Both companies intend to procure their own shares through on-market purchases commencing October 24th.
메이저 바카라 Group believes that the approval of this merger proposal and the post-merger plans to enhance shareholder value have fortified their foundation to advance as a global pharmaceutical powerhouse. The group anticipates three significant effects from this merger.
A spokesperson from 메이저 바카라 Group expressed, "By integrating the entire business cycle, from development to sales, we foresee improved cost competitiveness, which will provide substantial funding for the development of new drugs and modalities. This merger represents a pivotal moment, enabling us to pursue an assertive pricing strategy through strengthened cost competitiveness, thereby expanding our presence in sales regions and market share."
The spokesperson continued, "Furthermore, as the two companies integrate, the transaction structure will become more straightforward, enhancing financial metrics and transparency, ultimately bolstering investor trust. With the merger proposal's approval and the recent green light for the new drug 'Zymfentra' (known as 'Remsima SC' in the United States), 메이저 바카라 Group is one step closer to realizing the vision of 'Integrated 메이저 바카라,' aiming for .9 billion in revenue by 2030, and asserting itself as a global pharmaceutical leader."
The spokesperson concluded, "Moreover, with the smooth progression of the development and approval process for five new pipeline products set to debut from next year, 메이저 바카라 Group will focus on leveraging its strengths and making comprehensive efforts to expedite growth."